Market volatility presents both risk and opportunity. We analyze two fundamentally sound yet turbulent stocks that may reward the patient, and flag one whose wild swings are best left to speculators.
Citizens JMP reaffirms its bullish stance on Salesforce, citing the explosive growth of its AI platform Agentforce and strong enterprise adoption as key catalysts for sustained outperformance.
A new report reveals a staggering 67% of purchased sales software features go unused, spotlighting a critical disconnect between tech spending and revenue impact. As IT budgets swell, C-suite leaders are urged to shift from measuring adoption to calculating true dollar-for-dollar returns.
Since its spin-off from GE Aerospace, GE Vernova's stock has soared over 400%. While its position in gas, wind, and next-gen nuclear power is formidable, sky-high valuations give even growth investors pause.
Goldman Sachs raises its price target for Zeta Global (ZETA), citing strategic positioning ahead of an expected surge in software sector mergers and acquisitions driven by valuation gaps and synergy potential.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
TD Cowen lowered its price target on Atlassian (TEAM) ahead of earnings, highlighting strong fundamentals in service management and cloud migration but flagging weak traction in AI as a key medium-term overhang for the stock.
Analysts at Bernstein reaffirm an Outperform rating for Datadog, noting the company's strategic focus appears to be on internal development and smaller tech tuck-ins rather than pursuing large-scale deals like a potential GitLab acquisition.
A detailed Discounted Cash Flow analysis suggests Eagle Eye Solutions Group (LON:EYE) shares are trading close to their estimated intrinsic value. We examine the assumptions behind the numbers and what investors should consider beyond the model.
JPMorgan reiterates its Overweight rating on ServiceNow (NOW) with a $215 price target, following checks with nine ecosystem partners. While growth expectations have moderated slightly, the firm finds AI is fueling expansion and mission-critical projects continue unabated.
Despite recent market turbulence, a surge in eurozone business confidence is spotlighting companies where high insider ownership aligns management with shareholder interests. We examine three such firms poised for growth.
As the software sector faces a broad sell-off, Figma's valuation is being scrutinized through a dual lens: fears of AI disruption to traditional design work and optimism over its own AI-integrated platform. With short interest easing, the market is weighing the company's long-term positioning at the convergence of collaboration and automation.
Coveo Solutions Inc. (TSE:CVO) shattered its own records in fiscal Q3 2026, fueled by historic new bookings and surging demand for its enterprise-grade AI relevance platform. The company's focus on grounding generative AI in secure, governed data resonates as clients move from experimentation to operational deployment.
The UK government's £25m investment in Octopus Energy's Kraken Technologies through the British Business Bank raises critical questions about the use of taxpayer funds to back an already scaled, global, and recently loss-making platform.
Amidst broader market volatility, a closer look reveals compelling opportunities in the UK's penny stock arena. We analyze three companies—Accesso Technology, ActiveOps, and Zotefoams—that combine niche market strength with evolving financial narratives for the discerning investor.
While the broader ASX has climbed nearly 10% over the past year, shareholders of cloud accounting giant Xero have watched their holdings plummet by 47%. This stark divergence raises questions about market sentiment versus the company's underlying performance, which shows surprising resilience.
Veeva Systems' stock has faced recent pressure, declining over 11% in the past year. A deep dive into its valuation reveals a stark contrast: a discounted cash flow model suggests significant upside, while its premium P/E ratio tells a more cautious tale. We examine the numbers and what they mean for investors eyeing the life sciences cloud leader.
